Program
[Chairperson’s Special Session] February 14, 2020
Current problems on the risk communication
- Kazuya Nakayachi, Doshisha University, Japan
- Fumitaka Shibata, Tokyo University of Agriculture, Japan
[Special Session 1] February 13, 2020
Risk assessment of regenerative medicine
- Shin Kawamata, Foundation for Biomedical Research and Innovation, Japan
- Satoshi Yasuda, National Institute of Health Sciences, Japan
[Special Session 2] February 14, 2020
Hepatotoxicity in the immunotherapy of cancer
- Timothy W. Affolter, Phizer Inc., USA
[Symposium 1] February 13, 2020
Risk assessment of medical devices
- Yuji Haishima, National Institute of Health Sciences, Japan
- Hitomi Hagiwara, Terumo Corporation, Japan
- Yasushi Miyauchi, Kamakura Techno-Science, Inc., Japan
[Symposium 2] February 14, 2020
Spreading of the wing of JSTP
- Yong Hyun Jung, DT &CRO, Korea
- Yasuhiro Tanaka, Suntory MONOZUKURI Expert LTD. / ILSI Japan
- Klaus Weber, AnaPatbh GmbH and AnaPath Services GmbH, Switzerland
[Symposium 3] February 14, 2020
Modernization of toxicologic pathology
- Hiroshi Suemizum Central Institute for Experimental Animals, Japan
- Atsuhiko Kato, Chugai Pharmaceutical Co., Ltd, Japan
- Katsuhiro, Miyajima, Tokyo University of Agriculture, Japan
[Workshop] February 13, 2020
Forefront of toxicologic pathology
- Norimitsu Shirai, Pfizer Inc., USA
- Shunji Nakatsuji, Altasciences Preclinical Seattle LLC, USA
- Naoaki Yamada, LSI Medience Corporation, Japan
- Satoshi Furukawa, Nissan Chemical Corporation, Japan
[IATP/JSTP Maronpot Guest Lecture] February 13, 2020
Confounders for kidney carcinogenesis in cancer bioassays
- Gordon C. Hard, Consultant in Toxicology, Pathology, Carcinogenesis, New Zealand